Microfluidic cell models have been established in recent years as suitable in vitro models for AD to study neuronal connectivity and the spread of tau pathology [17–23], and they can be used to test intervention (by, e.g. small molecules) against neuronal cell death (characterised by loss of synapses and neuronal network in the cell model), which is one of the main pathophysiological characteristics of the disease [15]. This evidence concerns the gene MAPT and Alzheimer disease.